Frederick Lewis Altice MD, MA
Professor of Medicine (Infectious Diseases) and of Epidemiology (Microbial Diseases); Director, Clinical and Community Research; Director, HIV in Prisons Program; Director, Community Health Care Van; Icon Professor of Medicine, University of Malaya-Centre of Excellence for Research in AIDS (CERiA); Professor of Epidemiology and Public Health, Division of Epidemiology of Microbial Diseases
Departments & OrganizationsYale Medical Group
Office of International Medical Student EducationInfectious Diseases
School of Public Health: Center for Interdisciplinary Research on AIDS
Internal Medicine: Viral Hepatitis Program | Infectious Diseases: AIDS Care Program
Frederick L. Altice is a professor of Medicine, Epidemiology and Public Health and is a clinician, clinical epidemiologist, intervention and implementation science researcher at Yale University School of Medicine and School of Public Health. Dr. Altice’s primary research project focuses on the interface between infectious diseases and substance use disorders and he has a special interest in Global Health. He also has a number of projects working in the criminal justice system, including transitional programs addressing infectious diseases, medication-assisted therapies (methadone, buprenorphine, extended release naltrexone), mental illness and social instability. Specific topics include alcohol and opioid use disorders on HIV treatment outcomes, HIV and substance abuse treatment, interface with the criminal justice system, and pharmacokinetic drug interactions between treatment for substance use disorders and antiretroviral and tuberculosis therapy. His research has focused on development of and evaluation of interventions to improve adherence to antiretroviral therapy. Newer research interventions are using mobile technology to improve engagement in treatment and to promote medication adherence. Additionally, his research, using health services research techniques and implementation science, seeks to understand integration of methadone, buprenorphine and extended released naltrexone and its role in primary and secondary HIV prevention, including linkage to and retention in care. His work has emerged primarily with a global health focus with funded research projects internationally in Malaysia, Ukraine, Russia, Central Asia, Peru, and Indonesia. He has participated in projects through the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, Centers for Disease Control and Prevention, Substance Abuse and Mental Health Services Agency and the Center for Substance Abuse Treatment. He is currently also collaborating on projects with the WHO, UNAIDS, USAID, PEPFAR and UNODC. Current internationally funded projects in dedicated research sites that are being conducted in Malaysia, Ukraine, Moldova, Azerbaijan, Kyrgyzstan and Peru. His sites in Malaysia, Peru and Ukraine are dedicatedsites for the Global Health Equity Scholars Fogarty Training Program and the Doris Duke International Fellowship program.
- M.D., Emory University , 1986